Accolade, Inc. provides personalized, technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. Its customers are primarily employers that deploy Accolade solutions in order to provide employees and their families with a single place to turn for their health, healthcare, and benefits needs. It also offers medical opinion services to commercial customers and virtual primary care and mental health support. Its platform, True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, womenâs health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. Its offerings include Accolade Expert MD, Accolade Care, Plus and Connect and Accolade One.

Employees

2,400

Sector

Healthcare Facilities & Services

Calendar

2024-10-07 - Q2 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
24-09-17	4.310 $	+2.38%	656,712
24-09-16	4.210 $	-1.17%	458,167
24-09-13	4.260 $	+8.40%	946,856
24-09-12	3.930 $	+0.51%	660,345
24-09-11	3.910 $	-1.26%	898,018

Delayed Quote Nasdaq, September 17, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.310USD

Average target price

8.289USD

Spread / Average Target

+92.33%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-17 pm EDT			5-day change	1st Jan Change
4.310 ^USD	+2.38%		+8.84%	-64.11%

Sep. 05	Transcript : Accolade, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 09:15 AM
Jun. 28	Sector Update: Health Care Stocks Decline in Late Afternoon Trading	MT

Capitalization	337M	P/E ratio 2025 *	-3.96x	P/E ratio 2026 *	-4.48x
Enterprise value	608M	EV / Sales 2025 *	0.36x	EV / Sales 2026 *	0.29x
Free-Float	96.83%	Yield 2025 *	-	Yield 2026 *	-

Transcript : Accolade, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 09:15 AM	Sep. 05
Sector Update: Health Care Stocks Decline in Late Afternoon Trading	Jun. 28	MT
Sector Update: Health Care	Jun. 28	MT
Top Midday Decliners	Jun. 28	MT
Barclays Lowers Price Target on Accolade to $5.50 From $11, Maintains Equalweight Rating	Jun. 28	MT
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	Jun. 28	MT
Canaccord Genuity Adjusts Price Target on Accolade to $13 From $16, Maintains Buy Rating	Jun. 28	MT
Needham Cuts Accolade's Price Target to $8 From $13, Keeps Buy Rating	Jun. 28	MT
Investors Await Key Inflation Data as US Futures Trend Higher Pre-Bell	Jun. 28	MT
Top Premarket Decliners	Jun. 28	MT
Morgan Stanley Halves Price Target on Accolade to $6 From $12, Keeps Equalweight Rating	Jun. 28	MT
Truist Adjusts Price Target on Accolade to $9 From $14, Maintains Buy Rating	Jun. 28	MT
Accolade, Inc. Reports Earnings Results for the First Quarter Ended May 31, 2024	Jun. 27	CI

Top Midday Decliners	Jun. 28	MT
Barclays Lowers Price Target on Accolade to $5.50 From $11, Maintains Equalweight Rating	Jun. 28	MT
Canaccord Genuity Adjusts Price Target on Accolade to $13 From $16, Maintains Buy Rating	Jun. 28	MT
Needham Cuts Accolade's Price Target to $8 From $13, Keeps Buy Rating	Jun. 28	MT
Morgan Stanley Halves Price Target on Accolade to $6 From $12, Keeps Equalweight Rating	Jun. 28	MT

Accolade, Inc. Stock

Equities

ACCD

US00437E1029

Healthcare Facilities & Services

Valuation: Accolade, Inc.

Chart: Accolade, Inc.

Latest news: Accolade, Inc.

Last Transcript: Accolade, Inc.

Analysts' recommendations: Accolade, Inc.

Press Releases: Accolade, Inc.

News in other languages: Accolade, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Accolade, Inc.

ETFs: Accolade, Inc.

Other Healthcare Facilities & Services

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Accolade To Present at Morgan Stanley 22nd Annual Global Healthcare Conference	Aug. 28	AQ
First-of-its-kind Healthcare Innovation Provides Synchronized, Customized Whole-Health Strategies	Aug. 22	PR
Accolade To Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase	Aug. 07	AQ
Accolade, Inc. (ACCD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Jul. 15	BU
Accolade, Inc. (ACCD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Jul. 09	BU

MÄRKTE USA/Wall Street mit Abgaben - Nike knicken ein	Jun. 28
MÄRKTE USA/Börsen legen etwas zu - Nike unter Druck	Jun. 28
MÄRKTE USA/Gut behauptet nach Preisdaten im Rahmen der Erwartungen	Jun. 28
MÄRKTE USA/Nachlassende Inflation dürfte Wall Street stützen	Jun. 28
MARKT USA/Inflationsdaten dürften Richtung vorgeben	Jun. 28

1 day	+2.38%
1 week	+8.84%
Current month	-0.69%
1 month	+4.36%
3 months	-30.37%
6 months	-53.30%
Current year	-64.11%

Director	Title	Age	Since
Rajeev Singh CEO	Chief Executive Officer	56	15-09-30
Robert Cavanaugh PSD	President	55	15-11-01
Stephen Barnes DFI	Director of Finance/CFO	53	15-01-31

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES 1X ARK GENOMIC TRACKER ETP - USD	3.10%	1 M€	0.00%	-
ADVISORSHARES ALPHA DNA EQUITY SENTIMENT ETF - USD	0.97%	11 M€	-6.03%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ACCOLADE, INC.	+2.38%	+8.84%	-64.76%	-90.51%	337M
HCA HEALTHCARE, INC.	-1.47%	+2.86%	+55.10%	+53.63%	104B
CVS HEALTH CORPORATION	-0.93%	+1.56%	-18.40%	-32.37%	73.43B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.47%	-1.80%	+20.94%	+65.51%	27.6B
FRESENIUS SE & CO. KGAA	+1.18%	+2.41%	+14.34%	-15.64%	21.33B
LABCORP HOLDINGS INC.	+0.55%	+3.03%	+12.58%	-23.29%	18.96B
QUEST DIAGNOSTICS INCORPORATED	-0.63%	+1.65%	+23.10%	+0.39%	17.41B
NATERA, INC.	-1.90%	+7.14%	+147.01%	+0.67%	16.04B
TENET HEALTHCARE CORPORATION	-4.65%	+1.51%	+124.94%	+115.31%	15.77B
UNIVERSAL HEALTH SERVICES, INC.	-1.15%	+2.92%	+84.14%	+59.18%	15.68B
Average	-0.71%	+2.83%	+39.90%	+13.29%	31.07B
Weighted average by Cap.	-1.06%	+2.65%	+37.13%	+22.45%

Manager	Title	Age	Since
Rajeev Singh CEO	Chief Executive Officer	56	15-09-30
Michael Hilton BRD	Director/Board Member	60	15-11-01
Jeffrey Jordan BRD	Director/Board Member	65	16-06-30

	2025 *	2026 *
Net sales	467M	532M
Net income	-85.87M	-73.68M
Net Debt	-169M	-182M